Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches

Migraine and cluster headache (CH) are common, often chronic and disabling headache disorders for which many patients find conventional therapies ineffective or intolerable. Migraine affects nearly 15% worldwide and CH, though rarer (about 1 in 1,000), is among the most intensely painful conditions known. There are no pharmacological treatments developed specifically for CH, and roughly 20% of chronic CH cases are resistant to standard therapies. Dissatisfaction with established treatments and the rise in interest in complementary and alternative medicine have led some sufferers to explore illicit psychoactive substances—principally psychedelic tryptamines such as psilocybin and LSD—and cannabis, supported by anecdotal reports and a small number of studies suggesting possible benefits. The illegal status of many of these compounds has limited clinical research, leaving online patient communities as an alternative source of experiential data. The researchers set out to improve understanding of how people with CH and migraines use non-established or alternative pharmacological treatments. Specifically, they aimed to characterise why sufferers pursue these options, which substances and regimens are discussed and used, reported effects (acute and prophylactic), and adverse experiences, by analysing first‑person accounts posted on Internet discussion forums where sufferers exchange information and support.

The researchers conducted a qualitative thematic analysis of user-generated accounts in English-language online discussion forums. Initial Google searches for "cluster headache discussion forums" and "migraine discussion forums" were carried out on 18 April 2016 and supplemented by a search for "drug discussion forum" on 19 April 2016; the first 100 hits from each search were examined. From identified sites, two forums focused on alternative treatments (Shroomery.org and Bluelight.org) were selected and a third, Clusterbusters.org, was located via references. The forum internal search functions were used to identify topics. To keep the dataset manageable, the selection was restricted to topics initiated during the year prior to the search and excluded discussions limited to established medical treatments. Topics addressing triggers were included when relevant. In total, 32 topics were included; the extracted forum reports amounted to 56 pages of text. Coding was performed manually following Braun and Clarke’s approach to thematic analysis. The researchers read the data repeatedly and segmented it into basic units of meaning, producing 411 coded elements (CE). These CEs were grouped into 63 categories, and abstraction across categories yielded six principal themes. Throughout analysis, themes were iteratively revised by returning to the original material. Final themes and coding were reviewed by all authors and audited by two additional researchers experienced in thematic analysis. The extracted text does not clearly report participant demographics beyond the forum origins, nor does it provide independent verification of the reports.

The analysis generated six major themes: (1) a desperate need for effective treatments; (2) the role of forums in finding alternative treatments and providing community support; (3) the range of alternative treatment substances discussed; (4) dosage and regimens; (5) effects and treatment results; and (6) adverse effects. Under "a desperate need for effective treatments," forum posts described extreme suffering from CH and some severe migraines, including suicidal ideation and substantial functional impairment. Many reported perceived misdiagnosis or inadequate care and recounted failures of conventional therapies (including ergot derivatives, opioids, anticonvulsants and NSAIDs). Some users reported clinicians had suggested alternative or illicit treatments when conventional options failed. The "role of the forum" theme showed forums were used both to exchange practical information about substances, sourcing and dosing, and to provide empathy and peer support. Users discussed legal constraints and methods to obtain substances (including darknet and mail-order vendors for novel psychoactive substances), and the forums often emphasised harm‑reduction strategies and cautions about dangerous drug interactions (for example, serotonergic antidepressants with tryptamines). The "alternative treatment substances" theme identified a strong focus on psychedelic tryptamines—primarily psilocybin (mushrooms) and LSD—as well as related compounds (LSA-containing seeds, DMT, and various synthetic tryptamines such as 4‑A cO‑DMT, 4‑HO‑MET). Psilocybin and LSD were most commonly cited for both prophylactic and acute use. LSA seeds (e.g. Hawaiian Baby Woodrose, Rivea corymbosa) and novel synthetic tryptamines were discussed as more available or legal alternatives. Cannabis was discussed frequently but yielded more mixed reports. Other substances mentioned less often included ketamine, MDMA, melatonin, lidocaine, cocaine, opiates and supplements. In "dosage and regimens," three principal approaches were described: cyclic "busting" (timed moderate doses during CH cycles), frequent sub‑psychoactive "microdosing," and single or occasional full doses. Busting emphasised timing with cluster cycles, often dosing at intervals (examples include dosing every fifth day), while microdosing aimed for sub-perceptual doses taken more frequently to avoid psychoactive effects. Reported benchmark doses varied widely (e.g. psilocybin: commonly around 1 g dried Psilocybe cubensis, but 0.25–3 g discussed; LSD: ranges from micrograms to 150 μg depending on regimen). For DMT, some users reported that a full breakthrough dose was needed for lasting benefit. Regarding "effects and treatment results," many reports described substantial reductions in attack frequency and intensity, and some described full remissions following psychedelics. Both prophylactic and acute abortive effects were described for LSD and psilocybin, with some users reporting the need for occasional repeat doses to maintain benefit. Microdosing and busting were both reported as effective strategies for many users, though some individuals required full psychedelic doses. Cannabis reports were inconsistent—some users reported relief or reduced frequency of migraines, others reported no benefit or even triggering/worsening of attacks. Occasional reports described benefits from other substances (e.g. cocaine aborting an attack in one account). In "adverse effects," no severe adverse events were reported within the forum dataset. Reported issues included transient intensification of symptoms immediately after psychedelic dosing, anxiety or panic with psilocybin/LSD, occasional perspiration and focus problems with microdosing, mild nausea with LSA seeds, and cannabis reportedly triggering headaches in some users. The forums also contained accounts of risky behaviours related to sourcing, including use of novel psychoactive substances (NPS) and concerns about adulteration or impure supplies.

The researchers interpret the findings as complementing prior studies by illustrating why and how treatment‑resistant CH and migraine sufferers pursue non‑established pharmacological options via online communities. Desperation arising from severe, disabling pain and perceived failures of conventional care emerged as the main incentive for self‑treatment. Discussion forums functioned both as sources of practical information (substances, dosing, sourcing) and as supportive communities that emphasised harm reduction. The authors report that psychedelic tryptamines—primarily psilocybin and LSD—were frequently described by forum users as effective for both prophylactic and acute treatment of CH and migraines, including accounts of full remission in some cases. Three dosing strategies (busting, microdosing, and occasional full doses) were prominent, with some sufferers preferring microdosing to minimise psychoactive effects while others required higher doses for benefit. Cannabis produced highly variable reports, possibly reflecting heterogeneity in cannabinoids, strains, dosing and administration. The data also highlighted the use of novel and semi‑legal compounds and the attendant risks of NPS and impure or mislabeled illicit supplies. Key limitations acknowledged by the authors include the non‑random, self‑selected nature of the forum sample and the unverified accuracy of individual reports. Dosage, purity and concentration were often ill‑defined or missing, preventing firm conclusions about dose–effect relationships. The methodology does not allow precise differentiation of responses between CH and migraine, and many sufferers reported multiple headache types. The authors further note that although no severe adverse effects were reported in the dataset, long‑term effects remain unknown and the use of NPS has been associated elsewhere with harm, including fatal poisonings. The authors conclude that this vulnerable patient population often treats illicit psychoactive tryptamines as a last resort and that interactive forums produce reciprocal, harm‑reduction oriented knowledge. They call for more scientific studies to develop safe and effective therapies and suggest that legislative or ethical considerations (for example, exceptions to drug laws for medical use) may be required to minimise harm and address patient needs.

The authors conclude that self‑treatment of headache disorders is actively discussed in online support groups, with a predominant focus on illicit psychedelic tryptamines (psilocybin, LSD and related substances). Such use is frequently driven by desperation after failure of established treatments, and users report these substances as potential treatments for both migraine and CH. However, self‑experimenting with illegal or novel substances exposes sufferers to risks related to acquisition, unknown purity and potential adverse effects. Given the vulnerability of this population, the authors emphasise the need for more rigorous scientific studies and suggest that changes or exceptions in legislation, alongside ethical considerations, may be necessary to reduce harm and meet the needs of these patients.